Phreesia, Inc. (NYSE:PHR) Shares Purchased by Peregrine Capital Management LLC

Peregrine Capital Management LLC increased its holdings in shares of Phreesia, Inc. (NYSE:PHR) by 11.3% in the second quarter, Holdings Channel reports. The firm owned 354,607 shares of the company’s stock after acquiring an additional 36,047 shares during the period. Peregrine Capital Management LLC’s holdings in Phreesia were worth $7,518,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Conestoga Capital Advisors LLC increased its position in Phreesia by 1.0% during the 1st quarter. Conestoga Capital Advisors LLC now owns 78,085 shares of the company’s stock worth $1,869,000 after purchasing an additional 750 shares in the last quarter. ProShare Advisors LLC increased its position in Phreesia by 8.6% during the 1st quarter. ProShare Advisors LLC now owns 9,522 shares of the company’s stock worth $228,000 after purchasing an additional 751 shares in the last quarter. Swiss National Bank increased its position in Phreesia by 1.0% during the 1st quarter. Swiss National Bank now owns 104,300 shares of the company’s stock worth $2,496,000 after purchasing an additional 1,000 shares in the last quarter. Essex Investment Management Co. LLC grew its position in Phreesia by 1.9% in the first quarter. Essex Investment Management Co. LLC now owns 59,764 shares of the company’s stock valued at $1,430,000 after acquiring an additional 1,102 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Phreesia by 11.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,757 shares of the company’s stock valued at $295,000 after acquiring an additional 1,324 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on PHR shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a research report on Friday, May 31st. Stephens reaffirmed an “overweight” rating and issued a $28.00 price objective on shares of Phreesia in a research report on Friday, May 31st. JMP Securities reiterated a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a research note on Friday. Canaccord Genuity Group reduced their target price on Phreesia from $37.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, May 31st. Finally, Truist Financial reiterated a “buy” rating and set a $29.00 target price on shares of Phreesia in a research note on Monday, July 1st. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Phreesia has an average rating of “Moderate Buy” and an average price target of $30.54.

Insider Activity

In other news, CEO Chaim Indig sold 2,644 shares of the firm’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total transaction of $62,768.56. Following the transaction, the chief executive officer now directly owns 1,219,361 shares of the company’s stock, valued at $28,947,630.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Chaim Indig sold 2,644 shares of Phreesia stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total transaction of $62,768.56. Following the transaction, the chief executive officer now directly owns 1,219,361 shares of the company’s stock, valued at $28,947,630.14. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, General Counsel Allison C. Hoffman sold 14,110 shares of Phreesia stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $26.03, for a total value of $367,283.30. Following the transaction, the general counsel now directly owns 121,003 shares in the company, valued at $3,149,708.09. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 29,337 shares of company stock valued at $736,750. Company insiders own 5.80% of the company’s stock.

Phreesia Stock Performance

NYSE PHR traded up $0.28 during trading hours on Friday, hitting $25.71. The company had a trading volume of 290,990 shares, compared to its average volume of 461,355. Phreesia, Inc. has a fifty-two week low of $12.05 and a fifty-two week high of $30.70. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $22.92 and a 200-day simple moving average of $22.92. The firm has a market cap of $1.48 billion, a P/E ratio of -11.74 and a beta of 0.93.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Thursday, May 30th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.16. The company had revenue of $101.20 million for the quarter, compared to analyst estimates of $100.94 million. Phreesia had a negative return on equity of 46.89% and a negative net margin of 31.87%. The company’s quarterly revenue was up 20.8% compared to the same quarter last year. During the same period last year, the company earned ($0.70) earnings per share. Equities analysts predict that Phreesia, Inc. will post -1.16 EPS for the current year.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.